RVMD
Revolution Medicines Inc
200.90$
+0.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Revolution Medicines Inc (RVMD) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -387 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | -12 | -13 | -12 | -14 | -12 | -28 | -20 | -27 | -25 | -37 | -34 | -37 | -39 | -55 | -56 | -52 | -62 | -62 | -67 | -100 | -121 | -161 | -128 | -130 | -138 | -194 | -222 | -207 | -274 | -354 | -387 | -1,223 | |
| 1.1 | 0.7 | 0.8 | 0.8 | 0.9 | 0.9 | 1.5 | 1.7 | 1.6 | 1.7 | 1.7 | 1.8 | 1.8 | 2.1 | 2.3 | 2.3 | 2.4 | 2.6 | 2.5 | 1.8 | 2.1 | 2.9 | 2.8 | 2.8 | 0.1 | 3.4 | 3.7 | 3.8 | 4.3 | 33 | 4.5 | 4.5 | 47 | |
| – | 0.3 | 0.4 | 0.5 | 0.9 | 1.4 | 1.6 | 2.0 | 2.7 | 2.6 | 3.4 | 5.3 | 5.8 | 6.2 | 6.6 | 8.1 | 8.1 | 8.3 | 9.7 | 13 | 14 | 25 | 16 | 20 | 21 | 22 | 25 | 29 | 31 | 34 | 87 | 154 | 306 | |
| – | 0.5 | 1.0 | 0.5 | – | 1.4 | 1.5 | 2.1 | 3.1 | 3.2 | 3.4 | 6.0 | 6.8 | 7.1 | 6.7 | 8.1 | 7.8 | 5.7 | 9.7 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.6 | -4.3 | -2.7 | -2.5 | 0.6 | -12 | 3.5 | -4.5 | 4.3 | -5.7 | 2.4 | 7.8 | 4.2 | -7.1 | -5.0 | 12 | -14 | -2.9 | 21 | 1.1 | 21 | -47 | -4.7 | 13 | 43 | 2.4 | -4.3 | 56 | 32 | -17 | 15 | 87 | |
| 1.3 | 0.2 | 0.3 | 0.6 | 1.1 | 0.5 | 0.6 | 0.5 | 0.7 | 1.2 | 3.6 | 1.3 | 0.5 | 1.2 | 1.9 | 2.5 | 3.5 | 2.9 | 1.8 | 1.1 | 2.5 | 2.3 | 3.2 | 2.4 | 3.5 | 1.2 | 3.3 | 7.5 | 3.3 | 1.9 | 1.5 | 2.3 | 9.1 | |
| -1.3 | -0.1 | 5.8 | -56 | -60 | 8.0 | -60 | -136 | -101 | 63 | 2.3 | -123 | -30 | 8.5 | 44 | 62 | -123 | -7.1 | 4.0 | -44 | 77 | -380 | -248 | 108 | -21 | -393 | -16 | 34 | 25 | 75 | 173 | -1,659 | -1,386 | |
| 57 | 61 | 0.0 | – | 100 | 0.0 | 254 | 0.0 | – | 0.8 | 282 | 0.9 | 0.3 | 1.9 | 0.3 | 1.4 | 248 | 1.9 | 324 | – | – | 3.3 | – | 3.2 | – | 1.9 | – | 4.6 | – | -1.3 | – | 8.5 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 487 | – | |
| 57 | 4.2 | 0.0 | 90 | 10 | -1.5 | 254 | -1.3 | 169 | 1.5 | 282 | 0.9 | 0.3 | 11 | 0.3 | 1.4 | 248 | 51 | 324 | 65 | 1.0 | 839 | 0.8 | 7.5 | 77 | 874 | 0.9 | 257 | -1.6 | 366 | 239 | 2,420 | 3,023 | |
| 68 | -7.6 | -6.8 | 23 | -64 | -5.2 | 166 | -159 | 41 | 39 | 247 | -156 | -66 | -20 | -11 | 8.1 | 73 | -18 | 266 | -46 | -22 | 338 | -408 | -13 | -75 | 342 | -210 | 69 | -184 | 166 | 57 | 374 | 414 | |
| – | -12 | -13 | -12 | -15 | -12 | -29 | -20 | -28 | -26 | -41 | -35 | -37 | -40 | -57 | -58 | -55 | -65 | -64 | -68 | -103 | -123 | -164 | -131 | -134 | -140 | -198 | -229 | -211 | -276 | -356 | -390 | -1,232 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.